Roberta Sommaggio’s Post

Join Lymphoma Coalition, in collaboration with Medscape next Friday at the Satellite Symposium on Hematology! Lorna Warwick, CEO of Lymphoma Coalition, will bring the patient perspective to the forefront during the session - Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma 🗓️ Date: Friday, December 6, 2024 ⏰ Time: 3:30 PM - 5:00 PM PT This engaging panel discussion will feature: ✅ Differentiating between current and emerging bispecific antibodies ✅ Best practices for managing relapsed/refractory follicular lymphoma ✅ Patient-centered care and strategies for shared decision-making Don’t Miss Out! Discover cutting-edge insights from leading experts in follicular lymphoma, enriched by the invaluable perspective of a patient advocate. 🔗 Register now: https://lnkd.in/eiqp9egE #Lymphoma #PatientAdvocacy #BispecificAntibodies #Hematology #ASH2024

Dear Colleagues, A recent publication in the American Journal of Case Reports by authors from Kanazawa Medical University, Kanazawa, Japan, delves into Fluid overload-associated large B-cell lymphoma (FO-LBCL), a newly recognized subtype of large B-cell lymphoma. Highlighting an 80-year-old patient case, the paper underscores the complexity of diagnosing FO-LBCL due to its overlapping features with other conditions. Accurate diagnosis necessitates a comprehensive analysis of clinical imaging, morphology, and immunophenotype. This work provides valuable insights into differentiating FO-LBCL from other lymphomas, emphasizing the importance of precise diagnostic approaches to avoid misdiagnosis. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dTRmAsiR

4SC is headed to the #EORTC Cutaneous Lymphoma Tumour Group (CLTG) Annual Meeting from 9-11 October.   Reach out to us if you would like to meet our Chief Medical Officer Susanne Danhauser-Riedl or Head of Project Management Matthias Borgmann to learn about the #RESMAIN study which investigated the efficacy of #resminostat (#Kinselby) as a maintenance treatment for cutaneous T-cell lymphoma (#CTLC).   #EORTCCLTG #RESMAINstudy #RareDisease #BloodCancer

🌟 Roche Unveils Breakthrough Lymphoma Treatments with Durable Remissions! 🌟 At the 66th American Society of Hematology Annual Meeting, Roche showcased remarkable advancements in lymphoma care, introducing fixed-duration therapies like Columvi and Lunsumio that promise sustained remissions and improved patient outcomes. 🔍 Key Highlights: - 🩺 Columvi: 40% of patients with relapsed or refractory large B-cell lymphoma achieved a complete response, maintaining remission for nearly 30 months! - 🌿 Lunsumio: An impressive 64% remission rate in patients with relapsed or refractory follicular lymphoma over four years. - 💉 Innovative subcutaneous administration of Lunsumio offers a practical alternative to intravenous treatments, enhancing accessibility and reducing hospital visits. Roche's commitment to improving the quality of life for lymphoma patients shines through these innovative therapies. With flexible administration routes and durable remission rates, healthcare providers are now equipped with versatile tools for personalized treatment plans. Discover more about these groundbreaking developments by clicking the link! #CancerCare #ClinicalResearches #Hematology #InnovationInHealthcare #Lymphoma #Pharma #PharmaceuticalCompanies #Roche #MarketAccess #MarketAccessToday

We kick off #ESHLYMPHOMA2024 with a session on aggressive B cell lymphoma.  @AndrewDavies guided us through the biological features and clinical challenges of primary mediastinal lymphomas. Brief take-home messages from his session:   - PML is a thymic post-GC B-cell malignancy with unique biology - Patients benefit from intensified treatment (R-CHOP14 or da-EPOCH-R preferred over R-CHOP21) but side-effects have to be managed carefully  - Emerging role of anti-PD1 and CAR-T cell therapy in relapsed disease

Dear Colleagues, A recent publication in the American Journal of Case Reports by authors from Kanazawa Medical University, Kanazawa, Japan, delves into Fluid overload-associated large B-cell lymphoma (FO-LBCL), a newly recognized subtype of large B-cell lymphoma. Highlighting an 80-year-old patient case, the paper underscores the complexity of diagnosing FO-LBCL due to its overlapping features with other conditions. Accurate diagnosis necessitates a comprehensive analysis of clinical imaging, morphology, and immunophenotype. This work provides valuable insights into differentiating FO-LBCL from other lymphomas, emphasizing the importance of precise diagnostic approaches to avoid misdiagnosis. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dVVaYB5z

Dear Colleagues, A recent publication in the American Journal of Case Reports by the authors from Temple University Hospital, Philadelphia, Pennsylvania, USA, presents a rare case of non-IgM lymphoplasmacytic lymphoma (LPL). This rare subtype, constituting less than 5% of cases, poses diagnostic challenges due to its similarity to other B-cell lymphomas. The case report describes a 67-year-old woman with weight loss, anemia, and leukopenia, whose bone marrow biopsy revealed abnormal B cells lacking light chain expression but producing intracytoplasmic IgA. Neoplastic plasma cells also showed no definitive light chain expression. This case expands our understanding of non-IgM LPL, shedding light on its diagnostic nuances. The complete report is now available on the American Journal of Case Reports webpage. #MedicalResearch #Lymphoma #CaseReport | https://lnkd.in/dZWXrAgT

Anaplastic Large Cell Lymphoma –Tricky with Flow Cytometry? Part 2 See the first post for a full pdf of my thoughts. Here's the "on one foot" video presentation. Two very helpful journal articles to read: 1.      Kesler MV, Paranjape GS, Asplund SL, McKenna RW, Jamal S, Kroft SH. Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol. 2007 Aug;128(2):314-22. doi: 10.1309/GUHKGAJEJ72CEAL7. PMID: 17638668. https://lnkd.in/eg8_ygn6 2.      Muzzafar T, Wei EX, Lin P, Medeiros LJ, Jorgensen JL. Flow cytometric immunophenotyping of anaplastic large cell lymphoma. Arch Pathol Lab Med. 2009 Jan;133(1):49-56. doi: 10.5858/133.1.49. PMID: 19123736. https://lnkd.in/e3ZMAh8W #flowcytometry #lymphoma #ALCL

🔬 New study evaluates diagnostic tools for feline lymphoma Feline lymphoma is difficult to diagnose due to its variability, but a new research study is shedding light on how advanced diagnostic tools like flow cytometry and PARR can complement existing tests. According to Dr. Ira Gordon, “many cases of feline lymphoma arise in places that are difficult to sample or biopsy,” making these new tools vital for accurate diagnosis. Read the latest article on NEWStat to learn how these advancements could shape future feline care: https://bit.ly/4grM4Kv

AVR Treatment for Mantle Cell Lymphoma: Key Insights and Safety Data - Learn the Latest Findings from a 2-Year Study with an Interactive Quiz AVR shows promise as a chemotherapy-free regimen for MCL. Learn about efficacy, safety, and key results from this study: Wang M, Robak T, Maddocks KJ, Phillips T, Smith SD, Gallinson D, Calvo R, Wun CC, Munugalavadla V, Jurczak W. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024 Sep 10;8(17):4539-4548. doi: 10.1182/bloodadvances.2023012424. PMID: 38781315; PMCID: PMC11399641. #PharmacyEducation #OncologyPharmacist #MCL #ClinicalResearch #Hematology #CancerTreatment #PharmacistLeadership #PharmacyUpdates